原发性肝癌患者血清leptin,VEGF和AFP表达的意义

目的:探讨HCC患者血清Lep,VEGF和AFP表达的临床意义.方法:用ELISA检测30例健康对照、31例肝硬化和146例HCC患者血清Lep,VEGF和AFP含量,分析Lep,VEGF和AFP及其联合检测对HCC的诊断、临床分期和预后的意义.结果:HCC患者血清Lep水平与BMI显著相关(r=0.64,P<0.01),且显著低于肝硬化组/健康对照组(19μg/Lvs35,27μg/L,P<0.05).随TNM分期增加和转移、复发,HCC血清Lep水平明显降低(P<0.05).HCC患者血清VEGF水平显著高于肝硬化组/健康对照组(398ng/Lvs179,167ng/L,P<0.01),VEGF和AFP间无相关性,二者对HCC诊断的敏感性和特异性分别为71.2%,73.3%和80.6%,83.9%,联合检测可提高诊断的敏感性(91.8%)和准确度(90.4%).HCC患者VEGF水平与肿瘤大小呈正相关(<3cm:237±96ng/L,>3cm:398±124ng/L,P<0.01),Ⅲ,Ⅳ期患者血清VEGF水平也明显高于Ⅰ,Ⅱ期患者(346±131,401±152ng/Lvs228±89,259±102ng/L,P<0.01),术后转移和复发患者血清VEGF水平明显升高(P<0.05).结论:血清Lep测定可判断HCC患者营养状况和预后,血清VEGF与AFP联合测定可作为诊断HCC和判断其预后的重要指标.     

肝细胞癌患者血清DcR3水平与临床意义

目的:探讨血清DcR3水平对HCC的诊断价值及临床意义.方法:采用ELISA检测67例HCC、8例肝硬化、17例胆囊炎患者和28例正常人血清DcR3水平; 化学发光法测定血清AFP水平; 免疫组织化学二步法检测HCC癌组织中DcR3蛋白的表达.结果:HCC组和肝硬化组血清DcR3水平均明显高于正常对照组( P<0.01), HCC血清DcR3水平与伴有肝硬化、包膜浸润和复发转移有关( P<0.05). DcR3蛋白在HCC癌组织中的表达与血清水平呈正相关( r = 0.395, P<0.01), 但DcR3血清阳性率明显高于癌组织IHC( P<0.05). AFP与DcR3联合检测对HCC的诊断灵敏度可由单项检测的82%和76%提高到93%.结论:血清DcR3升高在HCC的发生发展及浸润转移中起重要作用, 通过监测高危人群以及肝癌患者血清中的DcR3水平, 同时联合检测AFP, 可能对HCC的筛查、诊断和判断预后有一定意义.     

Hep Par 1、CD34及Cytokeratin在血清AFP阴性肝细胞癌诊断中的应用

目的:探讨Hep Par 1、CD34及Cytokeratin在血清[AFP(-)HCC]诊断及其在ICC、MAC鉴别诊断中的意义.方法:选取南通市肿瘤医院1989-2007年手术切除的70例[AFP(-)HCC]、6例ICC及24例MAC的石蜡标本,免疫组织化学染色法检测Hep Par 1、CD34及Cytokeratin在血清[AFP(-)HCC]中的表达.结果:Hep Par 1、CD34在血清AFP(-)HCC、ICC及MAC中的表达差异性均具有显著统计学意义(Hep Par 1:χ2=50.7937、9.5745及37.4532;CD34:χ2=67.0330、9.9836)及49.3927,均P<0.01).在分化不良组与分化较好组血清AFP(-)HCC中表达差异性的比较中,Hep Par 1与CD34、CK20、CK19的表达均有统计学意义(P<0.01或0.05).联合应用Hep Par1、CD34对AFP(-)HCC与ICC、MAC的鉴别诊断评价准确度、灵敏度及特异度分别为:90.7%、89.8%及93.3%.结论:联合应用Hep Par 1、CD34及Cytokeratin可提高血清AFP(-)HCC的诊断准确率及其与ICC、MAC的鉴别诊断准确率,为临床治疗方案的选择与预测评估提供了病理依据.     

原发性肝细胞癌血清中miR-888-5p的表达及临床意义

背景miR-888-5p高表达于原发性肝细胞癌(hepatocellular carcinoma,HCC)组织及HCC细胞系,可促进肿瘤细胞侵袭及转移,与疾病分期及预后不良相关.然而HCC患者血清中miR-888-5p的表达水平尚未被检测,血清miR-888-5p对于HCC诊断及预后判断相关价值尚未被评估.目的检测HCC患者血清中miR-888-5p表达水平,探究其对HCC的诊断价值及与临床特征之间的关系.方法收集68例HCC患者、46例慢性乙型病毒性肝炎(chronic hepatitis B,CHB)患者、43例肝硬化(liver cirrhosis,LC)患者及40例同期健康体检者,实时荧光定量聚合酶链反应(quantitative real-time polymerase chain reaction,qRT-PCR)法检测血清中miR-888-5p表达量,受试者工作特征(receiver operating characteristic,ROC)曲线评估其诊断HCC的价值,并分析与HCC临床特征之间的关系.结果HCC患者血清中miR-888-5p表达量较CHB、LC及健康者显著上调(P<0.05).ROC曲线提示,联合检测ROC曲线下面积(area under curve,AUC)为0.907,敏感性91.18%,特异性72.50%)对HCC诊断价值优于分别检测血清miR-888-5p(AUC=0.737,敏感性79.41%,特异性62.50%)及甲胎蛋白(alpha-fetoprotein,AFP)(AUC=0.819,敏感性73.53%,特异性97.50%),且对AFP阴性HCC也具有较高的诊断价值:AUC=0.793,敏感性90.90%,特异性62.50%.此外,miR-888-5p表达水平与HCC肺转移相关(P=0.01).结论血清miR-888-5p对HCC及AFP阴性HCC具有较高诊断价值,与AFP联合检测诊断价值更高.miR-888-5p表达水平与HCC肺转移相关,有望成为HCC早期诊断及评估预后的新型血清学分子标志物.     

血清甲胎蛋白和高尔基体糖蛋白73联合检测对肝细胞癌的早期诊断价值

目的探讨血清甲胎蛋白(AFP)和高尔基体糖蛋白73(GP73)联合检测对肝细胞癌(HCC)的诊断价值,为早期诊断和鉴别诊断HCC提供依据。方法收集2012年6月-2013年5月住院患者标本共408例,其中HCC患者142例(HCC组),慢性肝炎患者156例(慢性肝炎组),肝硬化患者110例(肝硬化组)。分别采用电化学发光法和酶联免疫吸附试验(ELISA)双抗体夹心法测定3组患者的血清AFP和GP73的浓度,检测结果组间比较采用方差分析,率的比较采用χ2检验。并使用MedCalc统计学软件计算2项指标联合检测对HCC诊断的敏感度和特异度。结果 HCC组血清AFP和GP73的浓度显著高于肝硬化组和慢性肝炎组,差异具有统计学意义(P0.05);肝硬化组血清AFP和GP73的浓度显著高于慢性肝炎组,其差异亦有统计学意义(P0.05)。二者联合检测肝细胞癌的敏感度为95.8%,特异度为98.6%,较单项检测差异具有统计学意义(P0.05)。结论血清AFP和GP73联合检测对HCC具有较高的诊断价值和临床意义,可作为HCC早期的诊断和鉴别诊断指标,值得在临床上推广。     

血清甲胎蛋白联合维生素K缺乏或拮抗剂Ⅱ诱导蛋白在肝细胞癌病理诊断中的应用价值

目的评价血清甲胎蛋白(AFP)及维生素K缺乏或拮抗剂Ⅱ诱导蛋白(PIVKA-Ⅱ)在肝细胞癌(HCC)病理诊断中的价值。方法回顾性研究2016年5月-12月于北京佑安医院肿瘤微创介入中心行超声引导下肝穿刺活组织检查的肝恶性肿瘤患者134例,其中术后病理证实为HCC患者103例,非HCC患者31例,对其血清AFP和PIVKA-Ⅱ的检测结果进行统计分析。2组间比较采用两独立样本秩和检验(Mann Whitney U检验)。采用Spearman秩相关检验分析AFP及PIVKA-Ⅱ的相关性,采用受试者工作特征曲线(ROC曲线)分析AFP及PIVKA-Ⅱ诊断HCC的效能,计算敏感度、特异度及ROC曲线下面积(AUC),AUC比较应用Z检验。结果 HCC组血清AFP和PIVKA-Ⅱ水平均明显高于非HCC组(P值均0.001);血清AFP诊断HCC的AUC为0.842,PIVKA-Ⅱ诊断HCC的AUC为0.863,二者联合诊断AUC为0.869,三者间差异均有统计学意义(P值均0.001)。血清AFP单独诊断HCC的敏感度为70.9%,特异度为90.3%;PIVKA-Ⅱ单独诊断HCC的敏感度为72.8%,特异度为77.4%。二者联合检测诊断HCC的敏感度为82.5%,特异度为77.4%。HCC患者血清AFP和PIVKA-Ⅱ表达存在相关性(r=0.207,P0.05)。结论在肝恶性肿瘤患者中,血清AFP及PIVKA-Ⅱ对HCC的鉴别诊断具有较高的临床价值。PIVKA-Ⅱ单项检测诊断HCC效能优于AFP,二者联合检测诊断HCC效能优于单项检测,血清AFP及PIVKA-Ⅱ检测能够为临床上拒绝行肝穿刺病理检查的肝肿瘤患者病理分型的初步推断提供依据,进而有益于后续规范治疗方案的选择及临床预后的评估。     

GPC3、GP73在肝细胞癌临床诊断中的价值

目的评价磷酯酰肌醇蛋白聚糖3(GPC3)、高尔基体蛋白73(GP73)的高表达对肝细胞癌(HCC)诊断价值。方法对39例HCC、31例肝硬化患者,基线时收集外周血及肝组织,采用ELISA法检测血清GPC3、GP73的表达量,实时定量逆转录PCR法(qRT-PCR)检测外周血单个核细胞(PBMC)及肝组织中GPC3 mRNA和GP73 mRNA的相对表达量;ROC曲线分析诊断的灵敏度、特异度等指标。结果 HCC组GPC3、GP73测量值显著高于肝硬化组(P0.001);GPC3诊断HCC的截断值9.3μg/L,ROC曲线下面积(AUC)=0.956,灵敏度为89.74%,特异度为96.77%,阳性预测值为97.2%,阴性预测值为88.2%,阳性似然比(+LR)27.82,阴性似然比(-LR)0.11;GP73诊断HCC的截断值77.68 ng/mL,AUC=0.937,灵敏度为92.31%,特异度为83.87%,阳性预测值为87.8%,阴性预测值为89.7%,+LR:5.72,-LR:0.092。结论 GPC3、GP73在HCC患者中表达明显增高,且灵敏度显著优于常规AFP,GPC3、GP73的特异度与常规AFP相近,因此GPC3、GP73有望成为一种新的较好、可靠的HCC无创诊断指标。     

PEG10诊断HCV相关性肝硬化和肝癌效果评价

目的评价PEG10对慢性丙型肝炎(HCV)相关性肝硬化和肝细胞癌(HCC)的诊断价值。方法选择HCV患者67例,根据临床诊断分为单纯慢性HCV组23例、肝硬化组25例和HCC组19例,收集患者性别、年龄、ChildPugh分级、ALT、AST和血清AFP等信息,同时采用RT-PCR法检测外周血PEG10 mRNA水平。结果 AFP的ROC曲线下面积(AUC)为0.768,当231 ng/mL为AFP诊断HCC的界值时,敏感度和特异度分别为52.63%和93.75%,PEG10mRNA的AUC为0.880,最佳诊断界值为2.09,此时敏感度和特异度分别为84.21%和87.50%,PEG10诊断效能稍高于AFP,但差异无统计学意义(P0.05);PEG10 mRNA水平与HCC患者性别、肿瘤数目、肿瘤大小和转移情况均不相关(P0.05)。结论 PEG10 mRNA在HCC患者的水平明显高于慢性HCV和肝硬化,同时PEG10 mRNA与肿瘤大小、数目、临床分期均不相关,是一种理想的HCC诊断指标。     

血清异常凝血酶原复合物在原发性肝癌诊断中的应用价值

目的探讨血清肿瘤标志物异常凝血酶原复合物(protein induced by vitamin K antagonist-Ⅱ,PIVKA-Ⅱ)和甲胎蛋白(alpha fetoprotein,AFP)在原发性肝癌(hepatocellular carcinoma,HCC)诊断效能的差异.方法采用电化学发光法对2016-04/2017-04天津市第二人民医院住院的初治的285例HCC患者、60例肝硬化患者、60例慢性病毒性肝炎患者(慢性乙型肝炎38例,慢性丙型肝炎22例)、30例其他慢性肝病患者(药物性肝炎14例,酒精性肝炎8例,非酒精性脂肪性肝炎8例)、25例胃、结直肠癌患者、40例健康对照人群进行血清PIVKA-Ⅱ和AFP测定.采用ROC曲线比较PIVKA-Ⅱ、AFP单独诊断HCC的效能以及敏感性和特异性;并探讨PIVKA-Ⅱ与肿瘤直径、BCLC分期等的相关性.结果血清PIVKA-Ⅱ和AFP在HCC组表达水平均高于其他病例组(均P0.01).PIVKA-Ⅱ诊断HCC的敏感性高于AFP(84.2%vs 70.9%,P0.001);PIVKA-Ⅱ诊断HCC的特异性高于AFP(81.4%vs 65.6%,P0.001).PIVKA-Ⅱ和AFP联合诊断的敏感性高于PIVKA-Ⅱ单项检测(89.5%vs 84.2%),但差异无统计学意义(P0.05).PIVKA-Ⅱ、AFP诊断HCC的ROC-AUC分别为0.865、0.768,PIVKA-Ⅱ诊断HCC的ROCAUC大于AFP(0.865 vs 0.768,P0.001).HCC患者血清PIVKA-Ⅱ水平与性别、肿瘤数目、有无微血管侵袭相关,与年龄、病毒感染、肿瘤直径、门静脉癌栓、Child-Pugh分级无关.HCC患者血清PIVKA-Ⅱ水平随着BCLC分期的升高而升高(H=48.70,P0.001).结论血清PIVKA-Ⅱ对HCC的综合诊断效能略优于AFP,HCC患者血清PIVKA-Ⅱ水平与性别、肿瘤数目、伴有微血管侵袭相关.     

血清甲胎蛋白、血管内皮生长因子、p53抗体诊断原发性肝细胞癌的临床价值

目的探讨血清甲胎蛋白(AFP)、血管内皮生长因子(VEGF)、p53抗体诊断原发性肝细胞癌(HCC)的临床价值。方法选取2011年9月至2014年6月我院收治的79例HCC患者作为病例组,选取同期我院收治的65例肝硬化(HC)患者作为对照1组,另外选取同期我院体检科确诊的72例健康对照者作为对照2组,所有患者均接受AFP、VEGF、p53抗体测定,其中AFP测定采用电化学发光法,VEGF、p53抗体测定采用酶联免疫吸附试验(ELISA)。结果 1病例组血清AFP、VEGF、p53抗体显著高于对照1组(P0.01),对照1组血清AFP、VEGF、p53抗体显著高于对照2组(P0.01)。2绘制受试者工作特征(ROC)曲线,得到AFP、VEGF、p53抗体诊断HCC的ROC曲线下面积(AUC)分别为0.843(95%CI,0.738~0.905)、0.827(95%CI,0.731~0.899)、0.634(95%CI,0.515~0.756),AFP-AUC与VEGF-AUC相比差异无统计学意义(P0.05),p53抗体-AUC显著低于AFP-AUC与VEGF-AUC,差异有统计学意义(P0.01)。由ROC曲线可知,AFP、VEGF、p53抗体诊断HCC的最佳cut-off值分别为197μg/L、233 ng/L、0.63 k U/L,由此得知这3个指标诊断HCC的灵敏度、特异度分别为84.81%、87.59%,82.28%、89.78%,65.82%、86.13%。结论血清AFP与VEGF诊断HCC的临床性能相当,而p53抗体诊断HCC的灵敏度较低。     

A prospective study of blood alpha-fetoprotein messenger RNA as a predictor of hepatocellular carcinoma in patients with cirrhosis

Summary. Blood alpha-fetoprotein messenger RNA (AFP mRNA) is thought to be a marker of hepatocellular carcinoma (HCC). Its value as a predictor of HCC in patients at risk is not known. A series of 201 patients with compensated cirrhosis (114 men, mean age 58 years) underwent surveillance with semi-annual ultrasound and serum alpha-fetoprotein measurements. Total RNA was extracted from peripheral blood mononuclear cells collected at different intervals and AFP mRNA was retrotranscribed and amplified by nested polymerase chain reaction. Ten patients with HCC and 30 blood donors were used as controls. Three patients with HCC, 39 with cirrhosis under surveillance and four blood donors circulated AFP mRNA (30, 20 and 13%, NS). During 50 months of surveillance, 27 patients with cirrhosis developed HCC: the tumour was detected more often in patients with higher than normal baseline serum AFP (≥7 IU/L) than in those with normal AFP levels (21% vs 9%, P  = 0.02). The incidence of HCC was the same in patients with and without AFP mRNA at baseline (15% vs 14%). In 53 patients, AFP mRNA was re-tested after 6–25 months of surveillance. HCC developed in two of 11 (18%) who were initially AFP mRNA positive and later became negative, in none of those who were initially negative and later became positive and in two of 39 (5%) who remained persistently negative. In conclusion, blood AFP mRNA is not a sensitive predictor of HCC in patients with compensated cirrhosis.     

肝细胞癌患者外周血单个核细胞Foxp3 mRNA水平变化*

目的 检测初发现未治疗肝细胞癌（HCC）患者外周血单个核细胞（PBMCs）中 Foxp3 mRNA水平变化及其与血清AFP水平的关系。方法 在HCC患者60例和健康人20例,采用RT-PCR法检测PBMCs中Foxp3 mRNA水平,常规检测血清AFP水平。结果 HCC患者和健康对照组外周血Foxp3 mRNA水平分别为（0.976±0.073）和（0.772±0.083）,差异有统计学意义（P<0.01）;经Pearson相关性分析显示,HCC患者外周血Foxp3 mRNA水平与AFP水平呈正相关（r＝0.226,P＝0.025）。结论 HCC患者PBMCs 中Foxp3水平明显升高,对肿瘤的发生发展可能具有一定的预测作用。     

Preoperative human-telomerase reverse transcriptase mRNA in peripheral blood and tumor recurrence in living-related liver transplantation for hepatocellular carcinoma

BACKGROUND/AIMS: In this study we evaluated the potential role of preoperative h-TERT mRNA expression in peripheral blood as a tool for predicting prognosis and tumor recurrence after living-related liver donor transplantation (LRLDT). METHODOLOGY: The study included patients with unresectable HCC who underwent LRLDT from July 1999 to May 2003. RESULTS: There was no significant difference between the survival curves of those patients who met the Milan criteria and those who did not. However, there was a statistically significant difference (p=0.032) between the survival curves of those patients with positive preoperative h-TERT mRNA expression, and those who either had an initially negative preoperative h-TERT mRNA or who converted from positive to negative after neoadjuvant immunochemotherapy. CONCLUSIONS: In conclusion, the presence or absence of h-TERT mRNA in the peripheral blood may be a useful criterion in evaluating HCC patients for transplantation, as well as a valuable method of assessing anti-tumor therapy and tumor relapse.     

Clinical significance of cylindromatosis expression in primary hepatocellular carcinoma

Background and study aimThere is currently a lack of sensitive biomarkers for the diagnosis of hepatocellular carcinoma (HCC). Low expression of cylindromatosis (CYLD), a tumor suppressor gene that encodes a deubiquitinase, is associated with the development of HCC. The present study, therefore, aimed to determine the clinical utility of measuring CYLD expression in the early diagnosis of HCC.Patients and methodsThe present study comprised 257 patients from the Affiliated Hospital of Qingdao University including 90 patients with HCC, 41 patients with liver cirrhosis (LC), 46 patients with hepatitis B (HB), and 80 healthy controls. qPCR was used to measure the amounts of CYLD mRNA in stored blood samples. The sensitivity and specificity of CYLD mRNA in diagnosing HCC was analyzed using receiver operator characteristic (ROC) curves. We also obtained HCC data from the Oncomine database to further verify our results.ResultsThe relative levels of CYLD mRNA in peripheral blood from patients with HCC (median, 0.060; interquartile range [IQR], 0.019–0.260) was significantly lower than in blood from patients with LC (median, 3.732; IQR, 0.648–14.573), HB (median, 0.419; IQR, 0.255–1.809) and healthy controls (median, 1.262; IQR, 0.279–3.537; P < 0.05). CYLD mRNA levels in peripheral blood were significantly higher in patients with LC compared to healthy controls and patients with HB. Oncomine data demonstrated that CYLD mRNA expression levels in HCC tissues were significantly lower than in normal liver tissues. ROC analysis demonstrated that the combined use of peripheral blood levels of CYLD and AFP had the greatest diagnostic accuracy for HCC (area under the curve (AUC), 0.897; 95 % confidence interval [CI], 0.853–0.942). CYLD had utility as a supplementary marker to AFP for diagnosing HCC.ConclusionCirculating levels of CYLD mRNA are significantly decreased in patients with HCC, indicating CYLD may have utility as a biomarker of HCC. Combined measurement of CYLD mRNA and AFP protein had the greatest diagnostic accuracy.     

Clinical significance of cylindromatosis expression in primary hepatocellular carcinoma

Background and study aimThere is currently a lack of sensitive biomarkers for the diagnosis of hepatocellular carcinoma (HCC). Low expression of cylindromatosis (CYLD), a tumor suppressor gene that encodes a deubiquitinase, is associated with the development of HCC. The present study, therefore, aimed to determine the clinical utility of measuring CYLD expression in the early diagnosis of HCC.Patients and methodsThe present study comprised 257 patients from the Affiliated Hospital of Qingdao University including 90 patients with HCC, 41 patients with liver cirrhosis (LC), 46 patients with hepatitis B (HB), and 80 healthy controls. qPCR was used to measure the amounts of CYLD mRNA in stored blood samples. The sensitivity and specificity of CYLD mRNA in diagnosing HCC was analyzed using receiver operator characteristic (ROC) curves. We also obtained HCC data from the Oncomine database to further verify our results.ResultsThe relative levels of CYLD mRNA in peripheral blood from patients with HCC (median, 0.060; interquartile range [IQR], 0.019–0.260) was significantly lower than in blood from patients with LC (median, 3.732; IQR, 0.648–14.573), HB (median, 0.419; IQR, 0.255–1.809) and healthy controls (median, 1.262; IQR, 0.279–3.537; P < 0.05). CYLD mRNA levels in peripheral blood were significantly higher in patients with LC compared to healthy controls and patients with HB. Oncomine data demonstrated that CYLD mRNA expression levels in HCC tissues were significantly lower than in normal liver tissues. ROC analysis demonstrated that the combined use of peripheral blood levels of CYLD and AFP had the greatest diagnostic accuracy for HCC (area under the curve (AUC), 0.897; 95 % confidence interval [CI], 0.853–0.942). CYLD had utility as a supplementary marker to AFP for diagnosing HCC.ConclusionCirculating levels of CYLD mRNA are significantly decreased in patients with HCC, indicating CYLD may have utility as a biomarker of HCC. Combined measurement of CYLD mRNA and AFP protein had the greatest diagnostic accuracy.     

原发性肝癌患者外周血中甲胎蛋白mRNA的意义

目的由于ＰＣＲ技术的应用,血循环中癌细胞的检测近有很大进展．本文用ＲＴＰＣＲ检测肝癌（ＨＣＣ）和其他慢性肝病患者外周血中ＡＦＰｍＲＮＡ,藉以反映ＨＣＣ细胞的存在,并与其他血清标记物比较．方法ＨＣＣ患者２２例,肝硬变和慢性乙型肝炎患者各１０例,健康成人受试者（对照）５例．取患者和对照的外周血,分离单核细胞,提取总ＲＮＡ并作电泳鉴定,用合成的两对引物进行巢式ＲＴＰＣＲ扩增ＡＦＰｍＲＮＡ,同时分析血清ＡＦＰ和乙肝标记物．结果ＡＦＰｍＲＮＡ在１３例ＨＣＣ（５９１％）,２例肝硬变（２００％）患者外周血中测到,其余标本均为阴性．ＡＦＰｍＲＮＡ阳性的１３例患者肿瘤均大于５ｃｍ,为晚期患者．在该１３例患者中仅有６例（４６１％）在血清中测到ＡＦＰ,但有１２例（９２３％）ＨＢｓＡｇ,抗ＨＢｅ,抗ＨＢｃ全阳性,而ＡＦＰｍＲＮＡ阴性的５例该３标记物全阴性．结论ＲＴＰＣＲ扩增ＡＦＰｍＲＮＡ是检测ＨＣＣ和肝硬变患者循环肝癌细胞的敏感方法．患者外周血中的ＡＦＰｍＲＮＡ有可能作为肿瘤转移和复发的标记对ＨＣＣ诊断、随访观察和疗效评定有较大临床意义．     

Detection of hepatoma cells in peripheral blood of HCC patients by nested RT-PCR

AIM:To offer a more simple method with a high sensitivity and specificity for detection of hepatoma cells in peripheral blood of the patients with HCC.METHODS:Improved nested RT-PCR method was used to detect the expression of AFP mRNA in nuclear cells separated from peripheral venous blood.RESULTS:AFP mRNA contained in tenhepatoma cells was detected from 2mL peripheral blood.CONCLUSION:The improved nested RT-PCR assay for AFP mRNA expressed in cancer cells in peripheral blood might be a valuable method for clinical diagnosis of HCC.